ClinVar Miner

Submissions for variant NM_000059.4(BRCA2):c.5312G>A (p.Gly1771Asp)

gnomAD frequency: 0.00021  dbSNP: rs80358755
Minimum review status: Collection method:
Minimum conflict level:
ClinVar version:
Total submissions: 35
Download table as spreadsheet
Submitter RCV SCV Clinical significance Condition Last evaluated Review status Method Comment
Evidence-based Network for the Interpretation of Germline Mutant Alleles (ENIGMA) RCV000031539 SCV000244456 benign Breast-ovarian cancer, familial, susceptibility to, 2 2015-08-10 reviewed by expert panel curation IARC class based on posterior probability from multifactorial likelihood analysis, thresholds for class as per Plon et al. 2008 (PMID: 18951446). Class 1 based on posterior probability = 0.000000153
Invitae RCV000044634 SCV000072647 benign Hereditary breast ovarian cancer syndrome 2024-02-01 criteria provided, single submitter clinical testing
Counsyl RCV000031539 SCV000154060 likely benign Breast-ovarian cancer, familial, susceptibility to, 2 2014-01-02 criteria provided, single submitter literature only
GeneDx RCV000168575 SCV000167372 benign not specified 2014-03-06 criteria provided, single submitter clinical testing This variant is considered likely benign or benign based on one or more of the following criteria: it is a conservative change, it occurs at a poorly conserved position in the protein, it is predicted to be benign by multiple in silico algorithms, and/or has population frequency not consistent with disease.
Ambry Genetics RCV000162664 SCV000213106 benign Hereditary cancer-predisposing syndrome 2014-11-19 criteria provided, single submitter clinical testing This alteration is classified as benign based on a combination of the following: seen in unaffected individuals, population frequency, intact protein function, lack of segregation with disease, co-occurrence, RNA analysis, in silico models, amino acid conservation, lack of disease association in case-control studies, and/or the mechanism of disease or impacted region is inconsistent with a known cause of pathogenicity.
CHEO Genetics Diagnostic Laboratory, Children's Hospital of Eastern Ontario RCV000768599 SCV000219350 likely benign Breast and/or ovarian cancer 2023-04-13 criteria provided, single submitter clinical testing
Illumina Laboratory Services, Illumina RCV000031539 SCV000383714 uncertain significance Breast-ovarian cancer, familial, susceptibility to, 2 2018-03-06 criteria provided, single submitter clinical testing This variant was observed in the ICSL laboratory as part of a predisposition screen in an ostensibly healthy population. It had not been previously curated by ICSL or reported in the Human Gene Mutation Database (HGMD: prior to June 1st, 2018), and was therefore a candidate for classification through an automated scoring system. Utilizing variant allele frequency, disease prevalence and penetrance estimates, and inheritance mode, an automated score was calculated to assess if this variant is too frequent to cause the disease. Based on the score, this variant could not be ruled out of causing disease and therefore its association with disease required further investigation. A literature search was performed for the gene, cDNA change, and amino acid change (if applicable). No publications were found based on this search. This variant was therefore classified as a variant of unknown significance for this disease.
Women's Health and Genetics/Laboratory Corporation of America, LabCorp RCV000044634 SCV000494421 benign Hereditary breast ovarian cancer syndrome 2015-04-09 criteria provided, single submitter clinical testing Variant Summary: The variant of interst causes a missense change in a non-conserved position with 3/5 in silico programs predicting a "benign" outcome. The variant of interest has an observed allele frequency of 41/121940 (1/2976) including 1 homozygous occurrence. Functional analysis through the use of allelic imbalance implicated the variant does not affect splicing (Caux-Moncoutier_2009). The variant of interest has been reported in multiple affected individuals, however, it has shown lack of co-segregation within one family with an affected individual not carrying the variant of interest (Carvallone_2010). In addition, the variant of interest was reported to co-occur with another potentially pathogenic BRCA2 variant, c.759_759delinsACA and a potentially pathogenic BRCA1 variant, c.212+3A>G. Furthermore, multiple reputable databases/laboratories (ARUP, UMD, SCRP, GeneDx and Ambry Genetics) and publications (Lindor_2012, Easton_2007, and Cunningham_2014) classify the variant as "likely benign/benign/polymorphism." Therefore, taken all together, the variant of interest is classified as benign.
Laboratory for Molecular Medicine, Mass General Brigham Personalized Medicine RCV000168575 SCV000538487 uncertain significance not specified 2016-03-28 criteria provided, single submitter clinical testing Variant identified in a genome or exome case(s) and assessed due to predicted null impact of the variant or pathogenic assertions in the literature or databases. Disclaimer: This variant has not undergone full assessment. The following are preliminary notes: Clinvar: 7 labs classify as LB/Ben; ExAC: 0.1% (6/11554) Latino chromosomes
Fulgent Genetics, Fulgent Genetics RCV000031539 SCV000575746 likely benign Breast-ovarian cancer, familial, susceptibility to, 2 2015-12-08 criteria provided, single submitter clinical testing
Department of Pathology and Molecular Medicine, Queen's University RCV000168575 SCV000588100 benign not specified 2017-04-20 criteria provided, single submitter clinical testing
ARUP Laboratories, Molecular Genetics and Genomics, ARUP Laboratories RCV000168575 SCV000602747 benign not specified 2018-07-18 criteria provided, single submitter clinical testing
Color Diagnostics, LLC DBA Color Health RCV000162664 SCV000683694 likely benign Hereditary cancer-predisposing syndrome 2015-03-10 criteria provided, single submitter clinical testing
Genome Diagnostics Laboratory, University Medical Center Utrecht RCV000031539 SCV000743306 likely benign Breast-ovarian cancer, familial, susceptibility to, 2 2017-07-28 criteria provided, single submitter clinical testing
Clinical Genetics DNA and cytogenetics Diagnostics Lab, Erasmus MC, Erasmus Medical Center RCV000031539 SCV000744467 benign Breast-ovarian cancer, familial, susceptibility to, 2 2015-09-21 criteria provided, single submitter clinical testing
PreventionGenetics, part of Exact Sciences RCV000034445 SCV000805720 likely benign not provided 2017-01-10 criteria provided, single submitter clinical testing
Mendelics RCV000031539 SCV001139112 likely benign Breast-ovarian cancer, familial, susceptibility to, 2 2019-05-28 criteria provided, single submitter clinical testing
Illumina Laboratory Services, Illumina RCV001028067 SCV001270127 uncertain significance Fanconi anemia complementation group D1 2018-03-06 criteria provided, single submitter clinical testing This variant was observed in the ICSL laboratory as part of a predisposition screen in an ostensibly healthy population. It had not been previously curated by ICSL or reported in the Human Gene Mutation Database (HGMD: prior to June 1st, 2018), and was therefore a candidate for classification through an automated scoring system. Utilizing variant allele frequency, disease prevalence and penetrance estimates, and inheritance mode, an automated score was calculated to assess if this variant is too frequent to cause the disease. Based on the score, this variant could not be ruled out of causing disease and therefore its association with disease required further investigation. A literature search was performed for the gene, cDNA change, and amino acid change (if applicable). No publications were found based on this search. This variant was therefore classified as a variant of unknown significance for this disease.
Genetic Services Laboratory, University of Chicago RCV000168575 SCV002070522 likely benign not specified 2019-07-29 criteria provided, single submitter clinical testing
National Health Laboratory Service, Universitas Academic Hospital and University of the Free State RCV000044634 SCV002504853 benign Hereditary breast ovarian cancer syndrome 2022-04-19 criteria provided, single submitter clinical testing
Genetics Program, Instituto Nacional de Cancer RCV000044634 SCV002515118 likely benign Hereditary breast ovarian cancer syndrome 2021-11-01 criteria provided, single submitter research
Sema4, Sema4 RCV000162664 SCV002536125 benign Hereditary cancer-predisposing syndrome 2020-09-28 criteria provided, single submitter curation
Center for Genomic Medicine, Rigshospitalet, Copenhagen University Hospital RCV000168575 SCV002550347 benign not specified 2023-08-15 criteria provided, single submitter clinical testing
Institute for Biomarker Research, Medical Diagnostic Laboratories, L.L.C. RCV000044634 SCV004014964 benign Hereditary breast ovarian cancer syndrome 2023-04-11 criteria provided, single submitter clinical testing
KCCC/NGS Laboratory, Kuwait Cancer Control Center RCV000031539 SCV004016827 benign Breast-ovarian cancer, familial, susceptibility to, 2 2023-07-07 criteria provided, single submitter clinical testing
CeGaT Center for Human Genetics Tuebingen RCV000034445 SCV004132987 likely benign not provided 2024-04-01 criteria provided, single submitter clinical testing BRCA2: BP4, BS3:Supporting, BS1
Biesecker Lab/Clinical Genomics Section, National Institutes of Health RCV000034445 SCV000043212 probably not pathogenic not provided 2012-07-13 no assertion criteria provided research Converted during submission to Likely benign.
Sharing Clinical Reports Project (SCRP) RCV000031539 SCV000054144 benign Breast-ovarian cancer, familial, susceptibility to, 2 2006-03-16 no assertion criteria provided clinical testing
Breast Cancer Information Core (BIC) (BRCA2) RCV000031539 SCV000146599 not provided Breast-ovarian cancer, familial, susceptibility to, 2 no assertion provided clinical testing
Department of Pathology and Laboratory Medicine, Sinai Health System RCV000168575 SCV000591959 benign not specified no assertion criteria provided clinical testing The BRCA2 p.Gly1771Asp variant was identified in 6 of 1934 proband chromosomes from individuals with breast cancer, ovarian cancer or prostate cancer and was not detected in 100 control chromosomes evaluated (Edwards 2003, Hadjisavvas 2003, Hondow 2011, Kauff 2002, Thirthagiri 2008, Toh 2008). The variant was listed in dbSNP (ID: rs80358755) “With probable-non-pathogenic allele” with a minor allele frequency of 0.0005 (1000 Genomes Project), and in the NHLBI Exome Sequencing Project (with a frequency of 0.0006 in European American alleles, increasing the likelihood that this may be a low frequency benign variant in certain populations of origin. The variant was also identified in HGMD, LOVD, the BIC database (43X with no clinical importance, 1X with unknown clinical importance), and in UMD (25X as a neutral variant). In UMD the variant was twice listed co-occur with a pathogenic variant in BRCA1 or BRCA2 (BRCA2 c.759 759delinsACA (p.Ser253ArgfsX24) and BRCA1 c.IVS5+3A>G (c.212+3A>G)), increasing the likelihood that this variant does not have clinical significance. Computational analyses (PolyPhen-2, SIFT, AlignGVGD) do not suggest a high likelihood of impact to the protein (though this information is not predictive enough to rule out pathogenicity), and two in silico studies using multifactorial likelihood-ratio models predict the variant to be neutral or of no clinical significance (Easton 2007, Lindor 2012). Furthermore, the p.Gly1771 residue is not conserved in mammals and lower organisms, and the variant amino acid aspartic acid (Asp) is present in rat and mouse, further increasing the likelihood that this variant is not clinically important. In summary, based on the above information, this variant meets our laboratory's criteria to be classified as benign.
Diagnostic Laboratory, Department of Genetics, University Medical Center Groningen RCV000031539 SCV000733266 benign Breast-ovarian cancer, familial, susceptibility to, 2 no assertion criteria provided clinical testing
Biochemical Molecular Genetic Laboratory, King Abdulaziz Medical City RCV001028067 SCV001190846 benign Fanconi anemia complementation group D1 2020-02-05 no assertion criteria provided clinical testing
Joint Genome Diagnostic Labs from Nijmegen and Maastricht, Radboudumc and MUMC+ RCV000168575 SCV001952004 benign not specified no assertion criteria provided clinical testing
Clinical Genetics Laboratory, Department of Pathology, Netherlands Cancer Institute RCV000168575 SCV002034335 benign not specified no assertion criteria provided clinical testing
Laboratory of Diagnostic Genome Analysis, Leiden University Medical Center (LUMC) RCV000168575 SCV002036522 benign not specified no assertion criteria provided clinical testing

The information on this website is not intended for direct diagnostic use or medical decision-making without review by a genetics professional. Individuals should not change their health behavior solely on the basis of information contained on this website. Neither the University of Utah nor the National Institutes of Health independently verfies the submitted information. If you have questions about the information contained on this website, please see a health care professional.